^
    Back
    Association details:
    Biomarker:IL6 elevation
    Cancer:Renal Cell Carcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Inlyta (axitinib) (VEGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma

    Published date:
    12/03/2022
    Excerpt:
    ...high baseline serum IL-6 levels were associated with worse survival outcomes and reduced T-cell responses in Pembro/Axi-treated advanced RCC patients.
    DOI:
    10.3390/cancers14235985